Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK043 in Angiogenic Sarcomas
NCT07014137Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lumipodlin in angiosarcoma, sponsored by University Health Network. Started Sep 2025; status: recruiting.
02
Drugs
lumipodlin
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on NCT07014137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014137.